{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:21:11Z","timestamp":1789579271321,"version":"build-2803163510"},"reference-count":60,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>In adulthood, spinal cord MRI abnormalities such as T2-weighted hyperintensities and atrophy are commonly associated with a large variety of causes (inflammation, infections, neoplasms, vascular and spondylotic diseases). Occasionally, they can be due to rare metabolic or genetic diseases, in which the spinal cord involvement can be a prominent or even predominant feature, or a secondary one. This review focuses on these rare diseases and associated spinal cord abnormalities, which can provide important but over-ridden clues for the diagnosis. The review was based on a PubMed search (search terms: \u2018spinal cord\u2019 AND \u2018leukoencephalopathy\u2019 OR \u2018leukodystrophy\u2019; \u2018spinal cord\u2019 AND \u2018vitamin\u2019), further integrated according to the authors\u2019 personal experience and knowledge. The genetic and metabolic diseases of adulthood causing spinal cord signal alterations were identified and classified into four groups: (1) leukodystrophies; (2) deficiency-related metabolic diseases; (3) genetic and acquired toxic\/metabolic causes; and (4) mitochondrial diseases. A number of genetic and metabolic diseases of adulthood causing spinal cord atrophy without signal alterations were also identified. Finally, a classification based on spinal MRI findings is presented, as well as indications about the diagnostic work-up and differential diagnosis. Some of these diseases are potentially treatable (especially if promptly recognised), while others are inherited as autosomal dominant trait. Therefore, a timely diagnosis is needed for a timely therapy and genetic counselling. In addition, spinal cord may be the main site of pathology in many of these diseases, suggesting a tempting role for spinal cord abnormalities as surrogate MRI biomarkers.<\/jats:p>","DOI":"10.1136\/jnnp-2018-318666","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T16:21:59Z","timestamp":1535386919000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Spinal cord involvement in adult-onset metabolic and genetic diseases"],"prefix":"10.1136","volume":"90","author":[{"given":"Cecilia","family":"Marelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Salsano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Letterio S","family":"Politi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Labauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,8,27]]},"reference":[{"key":"2020050722330886000_90.2.211.1","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/B978-0-444-53486-6.00038-7","article-title":"Hereditary and metabolic myelopathies","volume":"136","author":"Hedera","year":"2016","journal-title":"Handb Clin Neurol"},{"key":"2020050722330886000_90.2.211.2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000343049.00540.c8"},{"key":"2020050722330886000_90.2.211.3","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-305888"},{"key":"2020050722330886000_90.2.211.4","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu353"},{"key":"2020050722330886000_90.2.211.5","doi-asserted-by":"publisher","DOI":"10.1038\/ng2013"},{"key":"2020050722330886000_90.2.211.6","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1329395"},{"key":"2020050722330886000_90.2.211.7","doi-asserted-by":"publisher","DOI":"10.1159\/000102171"},{"key":"2020050722330886000_90.2.211.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5755-5"},{"key":"2020050722330886000_90.2.211.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2013.04.006"},{"key":"2020050722330886000_90.2.211.10","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001157"},{"key":"2020050722330886000_90.2.211.11","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/ana.24452","article-title":"LMNB1-related autosomal-dominant leukodystrophy: Clinical and radiological course","volume":"78","author":"Finnsson","year":"2015","journal-title":"Ann Neurol"},{"key":"2020050722330886000_90.2.211.12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1212\/01.wnl.0000198770.80743.37","article-title":"Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord","volume":"66","author":"van der Knaap","year":"2006","journal-title":"Neurology"},{"key":"2020050722330886000_90.2.211.13","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A1060"},{"key":"2020050722330886000_90.2.211.14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn178"},{"key":"2020050722330886000_90.2.211.15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1212\/01.wnl.0000438230.33223.bc","article-title":"Neuroimaging and clinical features in type II (late-onset) Alexander disease","volume":"82","author":"Graff-Radford","year":"2014","journal-title":"Neurology"},{"key":"2020050722330886000_90.2.211.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70129-1"},{"key":"2020050722330886000_90.2.211.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-0221-x"},{"issue":"Pt 8","key":"2020050722330886000_90.2.211.18","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/brain\/122.8.1589","article-title":"Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis","volume":"122 ( Pt 8","author":"Verrips","year":"1999","journal-title":"Brain"},{"key":"2020050722330886000_90.2.211.19","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1212\/WNL.0b013e3182635673","article-title":"Clinical reasoning: a case of treatable spastic paraparesis","volume":"79","author":"McKinnon","year":"2012","journal-title":"Neurology"},{"key":"2020050722330886000_90.2.211.20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1179\/1079026815Z.000000000409","article-title":"Spinal form cerebrotendinous xanthomatosis patient with long spinal cord lesion","volume":"39","author":"Abe","year":"2016","journal-title":"J Spinal Cord Med"},{"key":"2020050722330886000_90.2.211.21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410180517"},{"key":"2020050722330886000_90.2.211.22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ymgme.2015.08.012","article-title":"Biotinidase deficiency should be considered in individuals exhibiting myelopathy with or without and vision loss","volume":"116","author":"Wolf","year":"2015","journal-title":"Mol Genet Metab"},{"key":"2020050722330886000_90.2.211.23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11011-017-9984-5","article-title":"A treatable cause of myelopathy and vision loss mimicking neuromyelitis optica spectrum disorder: late-onset biotinidase deficiency","volume":"32","author":"Yilmaz","year":"2017","journal-title":"Metab Brain Dis"},{"key":"2020050722330886000_90.2.211.24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1352458516646087","article-title":"Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease","volume":"23","author":"Girard","year":"2017","journal-title":"Mult Scler"},{"key":"2020050722330886000_90.2.211.25","doi-asserted-by":"publisher","DOI":"10.1177\/0883073807300307"},{"key":"2020050722330886000_90.2.211.26","doi-asserted-by":"publisher","DOI":"10.1177\/1352458515596457"},{"key":"2020050722330886000_90.2.211.27","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19971128)73:1<5::AID-AJMG2>3.0.CO;2-U"},{"key":"2020050722330886000_90.2.211.28","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-005-0161-3"},{"key":"2020050722330886000_90.2.211.29","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1038\/ejhg.2016.65","article-title":"Neonatal screening for profound biotinidase deficiency in the Netherlands: consequences and considerations","volume":"24","author":"Wiltink","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"2020050722330886000_90.2.211.30","doi-asserted-by":"publisher","DOI":"10.1007\/BF02278134"},{"key":"2020050722330886000_90.2.211.31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.4103\/0972-2327.128574","article-title":"Clinical, hematological, and imaging observations in a 25-year-old woman with abetalipoproteinemia","volume":"17","author":"Nagappa","year":"2014","journal-title":"Ann Indian Acad Neurol"},{"key":"2020050722330886000_90.2.211.32","doi-asserted-by":"publisher","DOI":"10.1007\/s002340050670"},{"key":"2020050722330886000_90.2.211.33","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00586-014-3191-4","article-title":"Spine MR imaging features of subacute combined degeneration patients","volume":"23","author":"Sun","year":"2014","journal-title":"Eur Spine J"},{"key":"2020050722330886000_90.2.211.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-005-0016-5"},{"key":"2020050722330886000_90.2.211.35","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5511-x"},{"issue":"1-2","key":"2020050722330886000_90.2.211.36","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jns.2014.05.020","article-title":"Prevalence of MR imaging abnormalities in vitamin B12 deficiency patients presenting with clinical features of subacute combined degeneration of the spinal cord","volume":"342","author":"Jain","year":"2014","journal-title":"J Neurol Sci"},{"key":"2020050722330886000_90.2.211.37","first-page":"34","article-title":"Conventional MRI for diagnosis of subacute combined degeneration (SCD) of the spinal cord due to vitamin B-12 deficiency","volume":"25","author":"Xiao","year":"2016","journal-title":"Asia Pac J Clin Nutr"},{"key":"2020050722330886000_90.2.211.38","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A2261"},{"key":"2020050722330886000_90.2.211.39","doi-asserted-by":"publisher","DOI":"10.4065\/81.10.1371"},{"key":"2020050722330886000_90.2.211.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.10.032"},{"key":"2020050722330886000_90.2.211.41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.5.730"},{"key":"2020050722330886000_90.2.211.42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-016-9991-4","article-title":"Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency","volume":"40","author":"Huemer","year":"2017","journal-title":"J Inherit Metab Dis"},{"key":"2020050722330886000_90.2.211.43","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10545-016-9979-0","article-title":"Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency","volume":"40","author":"Morris","year":"2017","journal-title":"J Inherit Metab Dis"},{"key":"2020050722330886000_90.2.211.44","first-page":"50","article-title":"Nitrous Oxide-induced Subacute Combined Degeneration Presenting with Dystonia and Pseudoathetosis: A Case Report","volume":"25","author":"Chen","year":"2016","journal-title":"Acta Neurol Taiwan"},{"key":"2020050722330886000_90.2.211.45","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/ajad.12372","article-title":"Neurologic, psychiatric, and other medical manifestations of nitrous oxide abuse: A systematic review of the case literature","volume":"25","author":"Garakani","year":"2016","journal-title":"Am J Addict"},{"key":"2020050722330886000_90.2.211.46","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.4.563"},{"key":"2020050722330886000_90.2.211.47","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1001\/jamaneurol.2015.2141","article-title":"Longitudinally extensive nitrous oxide myelopathy with novel radiographic features","volume":"72","author":"Ernst","year":"2015","journal-title":"JAMA Neurol"},{"key":"2020050722330886000_90.2.211.48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/ajh.24611","article-title":"Dorsal column myelopathy after intrathecal chemotherapy for leukemia","volume":"92","author":"Pinnix","year":"2017","journal-title":"Am J Hematol"},{"key":"2020050722330886000_90.2.211.49","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jocn.2012.06.018","article-title":"Methotrexate-induced myelopathy mimicking subacute combined degeneration of the spinal cord","volume":"20","author":"Gosavi","year":"2013","journal-title":"J Clin Neurosci"},{"key":"2020050722330886000_90.2.211.50","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-013-6844-z"},{"key":"2020050722330886000_90.2.211.51","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-32372"},{"key":"2020050722330886000_90.2.211.52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.msard.2018.01.003","article-title":"Mitochondrial leukoencephalopathies: a border zone between acquired and inherited white matter disorders in children?","volume":"20","author":"Bindu","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"2020050722330886000_90.2.211.53","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/acn3.323","article-title":"A multiple sclerosis-like disorder in patients with OPA1 mutations","volume":"3","author":"Yu-Wai-Man","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"2020050722330886000_90.2.211.54","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000437308.22603.43"},{"key":"2020050722330886000_90.2.211.55","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.mito.2015.08.002","article-title":"Magnetic resonance imaging correlates of genetically characterized patients with mitochondrial disorders: A study from south India","volume":"25","author":"Bindu","year":"2015","journal-title":"Mitochondrion"},{"key":"2020050722330886000_90.2.211.56","doi-asserted-by":"publisher","DOI":"10.1007\/s00234-005-1415-3"},{"key":"2020050722330886000_90.2.211.57","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww068"},{"key":"2020050722330886000_90.2.211.58","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000079050.91337.83"},{"key":"2020050722330886000_90.2.211.59","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23598"},{"key":"2020050722330886000_90.2.211.60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/brain\/awx297","article-title":"Plasma oxysterols: biomarkers for diagnosis and treatment in spastic paraplegia type 5","volume":"141","author":"Marelli","year":"2018","journal-title":"Brain"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2018-318666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T18:12:29Z","timestamp":1601057549000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2018-318666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,27]]},"references-count":60,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,1,16]]},"published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1136\/jnnp-2018-318666"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2018-318666","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,27]]}}}